{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:40:39Z","timestamp":1790685639593,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Targeted alpha therapy of disseminated cancer is an emerging technique where astatine-211 is one of the most promising candidate nuclides. Although astatine has been known for over 70 years, its chemistry is still largely unexplored, mainly due to the lack of stable or long-lived isotopes. However, substantial amounts of astatine-211 can be produced in cyclotrons by the bombardment of natural bismuth. The astatine can be recovered from the resulting irradiated target material through either wet extraction or dry-distillation. Chloroform has become an important intermediate solvent for the recovery of astatine after production, especially following dry distillation. In this work, the radiochemistry of astatine in chloroform was investigated using evaporation, solvent extraction, chromatographic methods and molecular modeling. The extraction of astatine in chloroform led to the formation of multiple astatine species, allowing for evaporation of the solvent to dryness without any loss of activity. Radiolysis products of chloroform were shown to play an important role in the speciation of astatine forming both reactive and kinetically stable compounds. It was hypothesized that reactions with chlorine, as well as trichloromethyl hydroperoxide, forming polar astatine compounds are important reactions under the current experimental conditions.<\/jats:p>","DOI":"10.1038\/s41598-019-52365-5","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T11:03:13Z","timestamp":1572865393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Towards elucidating the radiochemistry of astatine \u2013 Behavior in chloroform"],"prefix":"10.1038","volume":"9","author":[{"given":"Emma","family":"Aneheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ekberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Albertsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sture","family":"Lindegren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"52365_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/159024b0","volume":"159","author":"DR Corson","year":"1947","unstructured":"Corson, D. R., MacKenzie, K. R. & Segr\u00e8, E. Astatine the element of atomic number 85. Nature 159, 24 (1947).","journal-title":"Nature"},{"key":"52365_CR2","first-page":"177","volume":"4","author":"MR Zalutsky","year":"2011","unstructured":"Zalutsky, M. R. & Pruszynski, M. Astatine-211: Production and Availability Curr Radiopharm. 4, 177\u2013185 (2011).","journal-title":"Astatine-211: Production and Availability Curr Radiopharm."},{"key":"52365_CR3","first-page":"1","volume":"28","author":"F Guerard","year":"2013","unstructured":"Guerard, F., Gestin, J.-F. & Brechbiel, M. W. Production of [211At]-Astatinated Radiopharmaceuticals and Applications in Targeted \u03b1-Particle Therapy. Cancer Bioth. Radiopharm. 28, 1\u201318 (2013).","journal-title":"Cancer Bioth. Radiopharm."},{"key":"52365_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1021\/ed030p616","volume":"30","author":"I Asimov","year":"1953","unstructured":"Asimov, I. The natural occurrence of short-lived radioisotopes J. Chem. Edu. 30, 616\u2013618 (1953).","journal-title":"Chem. Edu."},{"key":"52365_CR5","unstructured":"Magill, J., Pfennig, G., Dreher, R., S\u00f3ti, Z. Karlsruhe Nuclide Chart 9th Edition (Marktdienste Haberbeck GmbH, 2015)."},{"key":"52365_CR6","doi-asserted-by":"crossref","unstructured":"Vas\u00e1ros, L., Berei, K. Gmelin Handbook of Inorganic Chemistry 107\u2013128 (1985).","DOI":"10.1007\/978-3-662-05868-8_5"},{"key":"52365_CR7","unstructured":"Berei, K., Vas\u00e1ros, L. Organic chemistry of astatine. Chapter 10 (John Wiley & Sons Ltd., 1983)."},{"key":"52365_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1021\/jp9077008","volume":"114","author":"J Champion","year":"2010","unstructured":"Champion, J. et al. Astatine Standard Redox Potentials and Speciation in Acidic Medium. J. Phys. Chem. A 114, 576\u2013582 (2010).","journal-title":"J. Phys. Chem. A"},{"key":"52365_CR9","unstructured":"Woods, R. J., Pikaev, A. K. Applied Radiation Chemistry: Radiation Processing Chapter 6, Selected Topics in Radiation Chemistry (John Wiley & Sons, 1994)."},{"key":"52365_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros, G. et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 51, 311\u201328 (2010).","journal-title":"J Nucl Med."},{"key":"52365_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2967\/jnumed.115.167825","volume":"57","author":"S Palm","year":"2016","unstructured":"Palm, S. et al. & Al. Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors. J Nucl Med 57, 594\u2013600 (2016).","journal-title":"J Nucl Med"},{"key":"52365_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2214\/AJR.14.12554","volume":"203","author":"TJ Wadas","year":"2014","unstructured":"Wadas, T. J., Pandya, D. N., Sai, K. K. S. & Mintz, A. Molecular Targeted \u03b1-Particle Therapy for Oncologic Applications Am. J. Roentgenology 203, 253\u2013260 (2014).","journal-title":"J. Roentgenology"},{"key":"52365_CR13","first-page":"1944","volume":"38","author":"E Horak","year":"1997","unstructured":"Horak, E. et al. Radioimmunotherapy targeting of HER2\/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 38, 1944\u20131950 (1997).","journal-title":"J Nucl Med"},{"key":"52365_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11523-018-0550-9","volume":"13","author":"M Makvandi","year":"2018","unstructured":"Makvandi, M. et al. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. Targeted Oncology 13, 189\u2013203 (2018).","journal-title":"Targeted Oncology"},{"key":"52365_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/molecules23030581","volume":"23","author":"J Kozempel","year":"2018","unstructured":"Kozempel, J., Mokhodoeva, O. & Vlk, M. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators. Molecules. 23, 581 (2018).","journal-title":"Molecules."},{"key":"52365_CR16","doi-asserted-by":"crossref","unstructured":"Wilbur, D. S. Enigmatic astatine Nature Chem. 5 (2013).","DOI":"10.1038\/nchem.1580"},{"key":"52365_CR17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/ncomms2819","volume":"4","author":"S Rothe","year":"2013","unstructured":"Rothe, S. et al. Measurement of the first ionization potential of astatine by laser ionization spectroscopy. Nature Comm. 4, 1835 (2013).","journal-title":"Nature Comm."},{"key":"52365_CR18","first-page":"2654","volume":"362","author":"J Champion","year":"2009","unstructured":"Champion, J. et al. Determination of stability constants between complexing agents and At(I) and At(III) species present at ultra-trace concentrations Inorg. Chimica Acta 362, 2654\u20132661 (2009).","journal-title":"Chimica Acta"},{"key":"52365_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02614-2","volume":"7","author":"D Teze","year":"2017","unstructured":"Teze, D. et al. Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate. Scientific Reports 7, 2579 (2017).","journal-title":"Scientific Reports"},{"key":"52365_CR20","first-page":"235","volume":"15","author":"SJ Kennel","year":"2000","unstructured":"Kennel, S. J. Evaluation of 225Ac for Vascular Targeted Radioimmunotherapy of Lung Tumors Cancer Bioth. Radiopharm. 15, 235\u2013244 (2000).","journal-title":"Radiopharm."},{"key":"52365_CR21","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2967\/jnumed.116.186338","volume":"59","author":"S Poty","year":"2018","unstructured":"Poty, S. et al. a-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies\u2014Part 1. J Nucl Med 59, 878\u2013884 (2018).","journal-title":"J Nucl Med"},{"key":"52365_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejmech.2016.03.082","volume":"116","author":"T Ayed","year":"2016","unstructured":"Ayed, T. et al. 211At-labeled agents for alpha-immunotherapy: On the in vivo stability of astatine-agent bonds. Euro. J Med. Chem. 116, 156\u2013164 (2016).","journal-title":"Euro. J Med. Chem."},{"key":"52365_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/IJN.S2736","volume":"3","author":"S Sofou","year":"2008","unstructured":"Sofou, S. Radionuclide carriers for targeting of cancer. Int J Nanomedicine. 3, 181\u2013199 (2008).","journal-title":"Int J Nanomedicine."},{"key":"52365_CR24","first-page":"607","volume":"50","author":"RN Shaffer","year":"1952","unstructured":"Shaffer, R. N. alpha irradiation: effect of astatine on the anterior segment and on an epithelial cyst Trans. Am. Ophthalmological Soc. 50, 607\u2013627 (1952).","journal-title":"Ophthalmological Soc."},{"key":"52365_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/0883-2889(86)90273-X","volume":"37","author":"I Brown","year":"1986","unstructured":"Brown, I. Astatine-211: Its possible applications in cancer therapy. Int. J. of Rad. Appl. Instr. Part A. Appl. Rad. Isotop. 37, 789\u2013798 (1986).","journal-title":"Int. J. of Rad. Appl. Instr. Part A. Appl. Rad. Isotop."},{"key":"52365_CR26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2174\/1381612003399275","volume":"6","author":"MR Zalutsky","year":"2000","unstructured":"Zalutsky, M. R. & Vaidyanathan, G. Astatine-211-Labeled Radiotherapeutics An Emerging Approach to Targeted Alpha-Particle Radiotherapy. Curr. Pharm. Design 6, 1433\u20131455 (2000).","journal-title":"Curr. Pharm. Design"},{"key":"52365_CR27","first-page":"1729","volume":"35","author":"G Lucignani","year":"2008","unstructured":"Lucignani, G. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213. EJNMMI 35, 1729\u20131733 (2008).","journal-title":"EJNMMI"},{"key":"52365_CR28","doi-asserted-by":"crossref","unstructured":"Guerard F, Gestin, J-F., Brechbiel, MW. Production of [211At]-Astatinated Radiopharmaceuticals and Applications in Targeted \u03b1-Particle Therapy. Cancer Bioth. Radiopharm. 28 (2013).","DOI":"10.1089\/cbr.2012.1292"},{"key":"52365_CR29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.2967\/jnumed.116.178327","volume":"58","author":"T B\u00e4ck","year":"2017","unstructured":"B\u00e4ck, T. et al. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated \u03b1-Radioimmunotherapy with 211At-MX35-F(ab\u2032)2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival. J Nucl Med 58, 598\u2013604 (2017).","journal-title":"J Nucl Med"},{"key":"52365_CR30","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2014-11-612770","volume":"125","author":"JD Green","year":"2015","unstructured":"Green, J. D. et al. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood. 125, 2111\u20132119 (2015).","journal-title":"Blood."},{"key":"52365_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","volume":"50","author":"H Andersson","year":"2009","unstructured":"Andersson, H. et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab\u2019)2\u2013a phase I study. J Nucl Med 50, 1153\u201360 (2009).","journal-title":"J Nucl Med"},{"key":"52365_CR32","doi-asserted-by":"publisher","unstructured":"Hallqvist, A. et. al. Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations. Online, J Nucl Med e-pub ahead of print https:\/\/doi.org\/10.2967\/jnumed.118.220384 (2019).","DOI":"10.2967\/jnumed.118.220384"},{"key":"52365_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2967\/jnumed.107.046938","volume":"49","author":"MR Zalutsky","year":"2008","unstructured":"Zalutsky, M. R. et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 49, 30\u201338 (2008).","journal-title":"J Nucl Med."},{"key":"52365_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep12025","volume":"5","author":"E Aneheim","year":"2015","unstructured":"Aneheim, E. et al. Automated astatination of biomolecules \u2013 a stepping stone towards multicenter clinical trials. Scientific Reports 5, 12025 (2015).","journal-title":"Scientific Reports"},{"key":"52365_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10967-017-5364-1","volume":"314","author":"C Ekberg","year":"2017","unstructured":"Ekberg, C., Jensen, H., Mezyk, S. P., Mincher, B. J. & Skarnemark, G. Extraction of 211At from nitric acid solutions into various organic solvents for use as an \u03b1-source for radiation chemistry studies. J. Radioanal. Nucl. Chem. 314, 235\u2013239 (2017).","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"52365_CR36","first-page":"636","volume":"3","author":"ER Balkin","year":"2013","unstructured":"Balkin, E. R. et al. Evaluation of a Wet Chemistry Method for Isolation of Cyclotron Produced [211At]Astatine Appl. Sci. 3, 636\u2013655 (2013).","journal-title":"Sci."},{"key":"52365_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0969-8043(01)00044-6","volume":"55","author":"S Lindegren","year":"2001","unstructured":"Lindegren, S., B\u00e4ck, T. & Jensen, H. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 55, 157\u2013160 (2001).","journal-title":"Appl Radiat Isot."},{"key":"52365_CR38","unstructured":"Greenwood, N.N., Earnshaw, A. Chemistry of the elements 2nd edition, Chapter 17, (Butterworth Heinemann, 1997)."},{"key":"52365_CR39","first-page":"43","volume":"46","author":"OR Pozzi","year":"2017","unstructured":"Pozzi, O. R. & Zalutsky, M. R. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At \u03b1-particles Nucl. Med. Biol. 46, 43\u201349 (2017).","journal-title":"Med. Biol."},{"key":"52365_CR40","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2967\/jnumed.107.049833","volume":"49","author":"Lindegren.","year":"2008","unstructured":"Lindegren. et al. Direct Procedure for the Production of 211At-Labeled Antibodies with an e-Lysyl-3- (Trimethylstannyl)Benzamide Immunoconjugate. J Nucl Med 49, 1537\u20131545 (2008).","journal-title":"J Nucl Med"},{"key":"52365_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1023\/A:1023912728929","volume":"256","author":"A Sj\u00f6str\u00f6m","year":"2003","unstructured":"Sj\u00f6str\u00f6m, A. et al. Direct astatination of a tumour-binding protein, human epidermal growth factor, using nido-carborane as a prosthetic group. J Radioanal Nucl Chem 256, 191\u2013197 (2003).","journal-title":"J Radioanal Nucl Chem"},{"key":"52365_CR42","first-page":"700","volume":"46","author":"OR Pozzi","year":"2005","unstructured":"Pozzi, O. R. & Zalutsky, M. R. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: Effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles. J Nucl Med 46, 700\u2013706 (2005).","journal-title":"J Nucl Med"},{"key":"52365_CR43","first-page":"339","volume":"23","author":"W Doberenz","year":"1987","unstructured":"Doberenz, W., Fischer, S. & Dreyer, R. Zur Extraktion Definierter Astatformen. Isotopenpraxis 23, 339\u2013343 (1987).","journal-title":"Isotopenpraxis"},{"key":"52365_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.chroma.2014.02.043","volume":"1337","author":"S Lindegren","year":"2014","unstructured":"Lindegren, S., Jensen, H. & Jacobsson, L. A radio-high-performance liquid chromatography dual-flow cell gamma-detection system for on-line radiochemical purity and labeling efficiency determination. J. Chromatogr. A. 1337, 128\u2013132 (2014).","journal-title":"J. Chromatogr. A."},{"key":"52365_CR45","doi-asserted-by":"crossref","unstructured":"Snyder, L. R., Kirkland, J. J. & Glajch, J. L. The column in Practical HPLC Method Development, 2nd Edition Chapter 5. (John Wiley and Sons, 1997).","DOI":"10.1002\/9781118592014"},{"key":"52365_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/BF02061138","volume":"177","author":"S Truszkowski","year":"1994","unstructured":"Truszkowski, S. & Szym\u00e1nski, W. Stable products and radicals in the radiolysis of dichloromethane and 1,1,-dichloroethane gamma-irradiated in an oxygen-free atmosphere. J. Radioanal. Nucl. Chem 177, 415\u2013423 (1994).","journal-title":"J. Radioanal. Nucl. Chem"},{"key":"52365_CR47","doi-asserted-by":"publisher","first-page":"15595","DOI":"10.1002\/ange.201608746","volume":"128","author":"N Guo","year":"2016","unstructured":"Guo, N. et al. The Heaviest Possible Ternary Trihalogen Species,IAtBr-,Evidenced in Aqueous Solution: An Experimental Performance Driven by Computations. Angew.Chem. 128, 15595\u201315598 (2016).","journal-title":"Angew.Chem."},{"key":"52365_CR48","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41557-018-0011-1","volume":"10","author":"N Guo","year":"2018","unstructured":"Guo, N. et al. Experimental and computational evidence of halogen bonds involving astatine. Nature Chem. 10, 428\u2013434 (2018).","journal-title":"Nature Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52365-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:28:49Z","timestamp":1671290929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52365-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["52365"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-52365-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"4 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15900"}}